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Abstract: Although commonly associated with obesity, non-alcoholic fatty liver disease (NAFLD) is also present in the lean pop-
ulation representing a unique disease phenotype. Affecting 25% of the world’s population, NAFLD is associated with increased
mortality especially when progressed to non-alcoholic steatohepatitis (NASH). However, no approved pharmacological treatments
exist. Current research focuses mainly on NASH associated with obesity, leaving the effectiveness of promising treatments in
lean NASH virtually unknown. This study therefore aimed to evaluate the effect of liraglutide (glucagon-like peptide 1 analogue)
and dietary intervention, alone and in combination, in guinea pigs with non-obese NASH. After 20 weeks of high-fat feeding
(20% fat, 15% sucrose, 0.35% cholesterol), 40 female guinea pigs were block-randomized based on weight into four groups
receiving one of four treatments for 4 weeks: continued high-fat diet (HF, control), high-fat diet and liraglutide treatment (HFL),
chow diet (4% fat, 0% sucrose, 0% cholesterol; HFC) or chow diet and liraglutide treatment (HFCL). High-fat feeding induced
NASH with severe fibrosis. Liraglutide decreased inflammation (p < 0.05) and hepatocyte ballooning (p < 0.05), while increas-
ing hepatic a-tocopherol (p = 0.0154). Dietary intervention did not improve liver histopathology significantly, but decreased liver
weight (p = 0.004), plasma total cholesterol (p = 0.0175), LDL-cholesterol (p = 0.0063), VLDL-cholesterol (p = 0.0034), hep-
atic cholesterol (p < 0.0001) and increased hepatic vitamin C (p = 0.0099). Combined liraglutide and dietary intervention
induced a rapid weight loss, necessitating periodical liraglutide dose adjustment/discontinuation, limiting the strength of the find-
ings from this group. Collectively, this pre-clinical study supports the beneficial effect of liraglutide on NASH and extends this
notion to lean NASH.
Non-alcoholic fatty liver disease (NAFLD) is estimated to
affect about 25% of the world’s population [1]. Progression to
non-alcoholic steatohepatitis (NASH) promotes liver fibrosis
and is an important risk factor for metabolic dysfunction and
cardiovascular disease [2–4]. Although often associated with
obesity and insulin resistance, NAFLD in lean/non-obese and
even non-diabetic individuals is not a rare occurrence, with
reported prevalence ranging from 3 to 25% [5,6]. Conse-
quently, lean NAFLD represents a significant, albeit less rec-
ognized, end of the phenotypic spectrum of NAFLD [6].
Research efforts are currently engaged in developing novel
intervention strategies against NASH; however, no effective
pharmacological treatment option is presently available and
data supporting reliable effects of lifestyle (e.g. dietary) inter-
vention in lean NAFLD are lacking [7,8]. Furthermore, much
of the current clinical and pre-clinical research largely targets
obese NASH, potentially neglecting the lean NASH pheno-
type. Glucagon-like peptide 1 (GLP-1) receptor agonists may
hold promise as potential pharmacological treatment options
and have been found to improve both hepatic steatosis and
oxidative stress in obese mice and rats with steatosis or mild
(no/early stage fibrosis) NASH [9–14]. In human beings, an
investigator-initiated, randomized, controlled clinical trial
recently reported histological resolution of NASH in obese/
overweight patients treated for 48 weeks with the GLP-1
receptor agonist liraglutide [15]. This suggests that liraglutide
intervention may constitute a treatment option of NASH
although the effectiveness in more advanced disease (NASH
with severe fibrosis) remains poorly understood, especially in
the setting of lean NASH.
The absence of excessive adiposity suggests a phenotypic
uniqueness of lean NASH compared to obese NASH and implies
that translating results from obese pre-clinical models to the lean
phenotype may be challenging. The high-fat diet, as applied in
this study, does not cause excessive weight gain compared to a
normal chow diet [16,17]. Hence, high-fat-fed guinea pigs do not
display an obese phenotype and remain non-obese relative to
healthy chow-fed controls. In addition, key histological features
of NASH (steatosis, hepatocyte ballooning, inflammation and
fibrosis) induced by a high-fat diet are similar in guinea pigs and
human beings [17]. This suggests the non-obese NASH guinea
pig as a relevant in vivomodel with high face and predictive valid-
ity. Like human beings – but unlike rats and mice – guinea pigs
have a LDL-dominant lipoprotein profile and respond to different
pharmacotherapies (e.g. statins) similarly to reports from clinical
studies [16–19]. The present study therefore aimed to investigate
the effects of liraglutide and dietary intervention alone and in
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combination, in our validated guinea pig model [16,17]. Dietary
intervention constituted a switch from an unhealthy (high fat) to a
healthy (chow) diet similar to a clinical setting. In accordance with
the relationship between NAFLD and cardiovascular disease, and
recent findings of a cardiovascular protective effect of liraglutide,
we also investigated the effect of liraglutide on endothelial func-
tion as a secondary end-point [20,21].
Materials and Methods
Animals and experimental design. All animal experimentation was
approved by the Animal Experimentation Council under the Danish
Ministry of Environment and Food (identification code
201515020100621, date of approval: 3 July 2015), and in
accordance with the European Legislation of Animal Experimentation
2010/63/EU.
Forty female Dunkin Hartley guinea pigs (Envigo RMS B.V. Venray
5800 AN the Netherlands) weighing 500–650 g were group-housed in
floor pens with wood shavings, hay, straw and environmental enrich-
ment and maintained on a 12-hr light–dark cycle with temperatures
between 20 and 24°C. The guinea pigs were fed a high-fat high-sucrose
diet (20% fat, 15% sucrose, 0.35% cholesterol) for 20 weeks, after
which they were block-randomized based on weight into four groups
(n = 10): A high-fat diet (HF) group, which continued on the start-up
high-fat diet, a high-fat diet group treated with liraglutide (HFL), a
group changed to a chow diet (4% fat, 0% sucrose, 0% cholesterol;
HFC) and a group changed to a chow diet and treated with liraglutide
(HFCL) for 4 weeks until study termination, at which animals were
killed as previously described [16,17]. All diets (Ssniff Spezialdi€aten
GmbH, Soest, Germany) were stored at 20°C until use (table 1). The
exact dietary compositions are given in Table S1 and are similar to
previously used high-fat and chow diets [16,17]. Feed aliquots were
thawed twice weekly and food intake measured by weighing the amount
of food remaining prior to each refill. The dose of liraglutide (Novo
Nordisk A/S, Maløv, Denmark) was based on previous literature [9–14]
and a small pilot study aiming to induce a 10–15% weight loss.
Liraglutide was slowly titrated over a period of 9 days to 30 nmol/kg
body-weight (BW) twice a day (BID) and administered by subcutaneous
injections. During dose escalation, guinea pigs received 5.4 nmol/kg
BW BID for 2 days, then 10.8 nmol/kg BW BID for 2 days, followed
by 16.2 nmol/kg BW BID for 3 days and lastly 21 nmol/kg BW BID
for 2 days. Groups not treated with liraglutide (HF and HFC) were
injected with a corresponding volume of vehicle (50 nM phosphate,
70 mM NaCl, 0.05% Tween 80, pH 7.4).
Expectedly, the combination of liraglutide and dietary intervention
induced weight loss in the HFCL group. However, the weight loss
occurred more rapidly than predicted and approached 20% of the ini-
tial body-weight due to an almost complete cessation of food intake.
As 20% weight loss was defined as a humane end-point for this study,
this necessitated dose adjustment/discontinuation of the liraglutide
treatment in some animals. Dietary intervention was maintained, but
treatment with liraglutide was only fully resumed in animals that had
regained weight corresponding to a weight loss of <10% of their
initial body-weight. During adjustment, doses were 15 nmol/kg BW
BID for 2 days, then 21 nmol/kg BW BID for 2 days before being
increased to 30 nmol/kg BW BID. Consequently, none of the guinea
pigs in the HFCL group received uninterrupted treatment with liraglu-
tide during the 4-week intervention period. Three of 10 guinea pigs in
the HFCL group made it back to the original dose.
Plasma samples. Blood samples for the analysis of total cholesterol
(TC), triglyceride (TG), aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and lipoprotein fractions (VLDL, LDL and
HDL) were collected from the vena saphena in K3-EDTA microvettes
(Sarstedt, N€umbrecht, Germany) prior to (‘week 0’) and 2 weeks after
the initiation of the treatments, as previously described [22]. At these
time-points, guinea pigs from each of the four groups were block-
randomized based on weight and plasma analysed for either lipids
(n = 5) or ALT and AST (n = 5). At euthanasia (week 4), blood
samples were collected intracardially using a K3-EDTA flushed syringe
except for samples analysed for free fatty acids (FFA) and alkaline
phosphatase (ALP), which were collected in NaF and heparin
microvettes (Sarstedt), respectively. Plasma was obtained by
centrifuging blood samples at 2000 9 g for 4 min. at 4°C. AST, ALT,
ALP and FFA were analysed on a Cobas 6000 (Roche Diagnostic
Systems, Berne, Switzerland) according to the manufacturer’s
specifications. TC, TG and lipoprotein fractions were analysed at the
Lipoprotein Analysis Laboratory (Wake Forest School of Medicine,
Winston-Salem, NC, USA) as previously described [23]. L-arginine
and asymmetric dimethylearginine (ADMA) levels were measured by
HPLC [24] and plasma samples for quantification of ascorbic acid
(AA) and dehydroascorbic acid (DHA) were stabilized metaphosphoric
acid before analysis by HPLC as previously described [25–27]. 8-
Isoprostanes were analysed by ELISA according to the manufacturer’s
specifications (Cayman Chemicals, Ann Arbor, MI, USA). For the
determination of dihydrobiopterin (BH2) and tetrahydrobiopterin
(BH4), blood was stabilized in 0.1% dithioerythritol and centrifuged
(2000 9 g, 4 min., 4C), yielding a plasma fraction which was
analysed by HPLC as described elsewhere [28].
Liver samples.
Lipids and glycogen. The liver was rinsed in ice-cold phosphate-
buffered saline (140 mM NaCl, 10 mM phosphate, 3 mM KCl, pH 7.4,
Millipore, Billerica, MA, USA) and weighed. TG, TC and glycogen
content were analysed on homogenates from the left lateral lobe (lobus
hepatis sinister lateralis) on a Cobas 6000 according to the
manufacturer’s specifications, as described previously [16,17]. In short,
1 ml of extraction buffer (0.15 M sodium acetate and 0.75% Triton-X)
was added to the frozen samples which were subsequently homogenized.
The samples were then placed in a 100C water bath for two minutes,
before cooling on ice and supplemented with 0.5 ml extraction buffer.
Five hundred microlitres of homogenate was then centrifuged at 3400 g
for 10 min. at 4°C and the supernatant analysed for TG, TC and free
glucose. Total glucose was measured in 400 ll homogenate after
overnight incubation at room temperature with 20 ll amyloglucosidase
(Sigma, St. Louis, MO, USA). Subsequently, glycogen concentrations
were calculated by subtracting free glucose from total glucose.
Markers of oxidative stress. Vitamin C, L-arginine and ADMA were
quantified in liver homogenates as stated above. Hepatic levels of
glutathione (GSH) and oxidized glutathione (GSSG) were measured
according to Hissin and Hilf [29] and malondialdehyde (MDA) was
measured as described [30]. Superoxide dismutase (SOD) was measured
using colorimetry (Randox Superoxide Dismutase (Ransod assay),
Randox Laboratories Ltd, Crumlin, UK) according to the manufacturer’s
specifications. a-Tocopherol and c-tocopherol were analysed by
stabilizing liver homogenates with butylated hydroxytoluene and
otherwise proceeding as described by Burton et al. [31].
Table 1.
Dietary composition
Nutrient (%) High-fat high-sucrose Chow
Protein 16.7 16.8
Carbohydrates 37.9 47.1
Fat 20.0 4.2
Cholesterol 0.35 –
Sucrose (total amount added to diet) 15.0 –
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Histology. Sections of the left lateral lobe (lobus hepatis sinister
lateralis) were fixed in 4% paraformaldehyde in phosphate-buffered
saline for 72 hr at 4C, after which the tissue was stored in 1%
paraformaldehyde at 4C prior to embedding in paraffin [16,17].
Tissue samples were cut into 2- to 4-lm sections and stained with
haematoxylin and eosin and Masson’s trichrome and scored in a
blinded fashion in accordance with the semi-quantitative scoring
scheme suggested by Kleiner et al. [32]. The degree of steatosis,
ballooning (degenerating) hepatocytes and fibrosis were scored in the
entire liver section. Steatosis was graded as 0 (<5%), 1 (5–33%), 2
(>33–66%) or 3 (>66%) and ballooning as 0 (not present), 1 (few
ballooning hepatocytes) or 2 (many/prominent ballooning
hepatocytes). Lobular inflammation was scored in five lobuli (each
defined by the presence of at least two portal areas surrounding a
central vein) and assessed based on the number of inflammatory foci
(defined as at least three inflammatory cells in close proximity of each
other). Inflammation was scored as 0 (not present), 1 (<2 foci), 2 (2–4
foci) and 3 (>4 foci). Portal inflammation was assessed by
individually evaluating all portal areas for inflammation (defined by
the presence of ≥10 inflammatory cells) and scored as 0 (no
inflammation in any portal area) or 1 (inflammation in at least one
portal area). The presence of intracellular lipid depositions was
previously verified, in this model, by Oil Red O staining [16].
Fibrosis was evaluated on Masson’s trichrome-stained sections as
either 0 (not present), 1 (perisinusoidal or periportal), 2 (perisinusoidal
and periportal), 3 (bridging from central vein to central vein, central
vein to portal vein and/or portal vein to portal vein) or 4 (cirrhosis).
To assess disease severity, the NAFLD activity score was calculated
as the unweighted sum of steatosis, ballooning and inflammation,
ranging from 0 to 8 [32].
Endothelial dysfunction. Endothelial function was investigated in
coronary arteries from HF and HFL. After euthanasia, the heart was
isolated and placed into cold physiological buffer (117.8 mM NaCl,
4.0 mM KCl, 2.0 mM CaCl2, 0.9 mM MgCl2, 1.25 mM NaH2PO4,
20 mM NaHCO3 and 5.0 mM glucose). The left anterior descending
coronary artery was cleaned of surrounding myocardial tissue and cut
into segments (approximately 2 mm long) that were mounted in wire-
myograph organ chambers (Danish Myo Technology, Aarhus,
Denmark) filled with 5 ml physiological buffer (37°C, perfused with 5%
CO2 in air). The segments were progressively stretched to their optimal
internal circumference (IC1) equal to 90% of the internal circumference
(IC100) under a passive transmural pressure at 100 mmHg (13.3 kPa).
After an equilibrium period for 30 min., the segments were challenged
twice with 60 mM potassium (similar composition as the physiological
buffer, with NaCl exchanged by KCl in an equimolar basis). Only
segments with potassium-induced contraction >1 mN/mm were
included in the study. Vasodilator responses were determined by adding
increasing concentration of the muscarinic acetylcholine receptor
agonist carbachol (from 109 to 3 9 105 M) (Sigma-Aldrich, St.
Louis, MO, USA) to 60 mM potassium pre-contracted segments. To
elucidate the carbachol–vasodilator responses, the carbachol
concentration–response curves were obtained in the absence (controls)
or in the presence of either the cyclooxygenase inhibitor indomethacin
(104 M) (Sigma-Aldrich, St. Louis, MO, USA) or the endothelial nitric
oxide synthase inhibitor L-NAME (105 M) (Sigma-Aldrich). Active
tension was calculated by subtracting the passive tension from the
potassium-induced active tension. Carbachol-induced tension was
normalized to the potassium-induced active tension.
Statistical analysis. All statistical analyses were performed in SAS
Enterprise Guide 7.1 (SAS Institute Inc, Cary, NC, USA) and graphs
were made with GraphPad Prism 7 (GraphPad Software, La Jolla, CA,
USA). Weight, energy intake and endothelial function was analysed
by mixed linear model, while plasma TG, VLDL-TG, TC, VLDL-C,
LDL-C, HDL-C, ALT and AST were analysed with an ANCOVA with
baseline (week 0) as covariate. All other continuous data were
analysed with ANOVA. Multiple comparisons were corrected by
Tukey’s post hoc test after the ANCOVA or ANOVA. Continuous data are
presented as means with standard deviations (S.D.) while ordinal data
(liver histology) were analysed with Kruskal–Wallis test followed by
Dunn’s post hoc test [33] and presented as medians. Data with
inhomogeneous variances (plasma TG, VLDL-TG, TC, VLDL-C,
LDL-C, HDL-C, ALT, AST, L-arginine/ADMA and liver L-arginine/
ADMA) were log-transformed before analysis and then back-
transformed and presented as geometric means with 95% confidence
intervals. A p-value below 0.05 was considered statistically
significant.
Results
Body-weight and energy intake.
All groups displayed similar weight gain prior to liraglutide
and dietary intervention. Liraglutide treatment resulted in
weight loss of HFL and HFCL compared to HF (HFL/HFCL
versus HF p = 0.046/p = 0.0009, p < 0.0001/p < 0.0001,
p < 0.0001/p < 0.0001 and p < 0.0001/p < 0.0001 at weeks
21, 22, 23 and 24, respectively) and HFC (HFL/HFCL versus
HFC p = 0.0461/p = 0.0122, p = 0.0009/p < 0.0001, p =
0.0027/p < 0.0001 and p = 0.0004/p = 0.0003 at weeks 21,
22, 23 and 24, respectively). The change from high-fat to
chow diet in the HFC group seemed to result in weight stag-
nation, but the weight was not significantly different from that
of HF animals (fig. 1A). The average daily energy intake was
decreased for HFL compared to HF at weeks 1 (p < 0.0001),
2 (p < 0.0001) and 4 (p = 0.0018) post-intervention and in
HFC and HFCL compared to HF at weeks 1 (p < 0.0001 and
p < 0.0001, respectively), 2 (p < 0.0001 and p < 0.0001,
respectively), 3 (p = 0.005 and p = 0.0007, respectively) and
4 (p < 0.0001 and p < 0.0001, respectively). Energy intake
was lower in HFL compared to HFC at week 1 post-interven-
tion (p = 0.01) and lower in HFCL compared to HFL and
HFC at weeks 1 (p < 0.0001 and p < 0.0001, respectively)
and 2 post-intervention (p < 0.0001 and p < 0.0001, respec-
tively) (fig. 1B).
Liver histology and status.
High-fat feeding induced NASH and severe (grade 3) fibro-
sis with close resemblance to human histopathology, that is
bridging fibrosis and a pericellular/perisinusoidal (chicken
wire) fibrotic architecture originating from the central veins
alongside macro- and microvesicular steatosis, inflammation
and hepatocyte ballooning. Liraglutide decreased hepatocyte
ballooning in HFL compared to HF (p < 0.05) and inflam-
mation in HFL and HFCL compared to HF (p < 0.05;
fig. 2A,B). Although not reaching statistical significance,
hepatocyte ballooning was reduced in HFC and HFCL com-
pared to HF. Hepatic steatosis was lowered after dietary
intervention in HFC and HFCL compared to HFL (p < 0.05)
and also tended to be decreased compared to HF (fig. 2C).
Bridging fibrosis was observed in most HF animals (80%)
and was not significantly affected by treatments (fig. 2D).
Portal inflammation was not significantly different among
groups, although a nominal reduction was observed by
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treatment with liraglutide in HFL compared to HF (fig. 2E).
NAFLD activity scores were reduced in all treatment groups,
reaching statistical significance in HFCL compared to HF
(p < 0.05; fig. 2F).
In HFL, HFC and HFCL, the absolute liver weight was
decreased compared to HF animals (Table S2). Normalized to
body-weight only HFC (p = 0.004) and HFCL (p = 0.0311)
animals displayed significantly reduced liver weights
compared to HF. Likewise, hepatic cholesterol levels were
decreased in HFC and HFCL compared to HF (p < 0.0001
and p < 0.0001, respectively) and HFL (p = 0.0363 and
p = 0.0307, respectively), but not in HFL compared to HF.
Hepatic TG levels did not differ between groups. Liver glyco-
gen was not different between HF, HFL and HFC, but reduced
in HFCL compared to HF (p = 0.0335; table 2). ALT and
AST was elevated in HFCL compared to HF (p < 0.0001 and
Fig. 1. Body-weight and energy intake. (A) Body-weight increased similarly in all groups prior to intervention (indicated by the arrow) after which
the body-weight stagnated in HFC and decreased significantly in HFL and HFCL compared to HF and HFC. (B) The average daily energy intake
followed the changes in body-weight and decreased in HFL, HFC and HFCL compared to HF (B). (A) **p < 0.01 HFL/HFCL versus HF
†p < 0.05 HFL/HFCL versus HFC. Groups with different subscripts differs significantly from each other at the designated time-point with at least
p < 0.05. Means with S.D. n = 10.
Fig. 2. Liver histology and disease severity. (A) HFL displayed significantly fewer ballooning (degenerative) hepatocytes compared to HF animals,
(B) while HFL and HFCL reduced the degree of inflammation. (C) Dietary intervention reduced hepatic steatosis compared to HFL and tended to
reduce steatosis grade compared to HF. (D) Bridging fibrosis was observed in most animals and was not significantly affected by the interventions.
(E) Portal inflammation appeared to be reduced in HFL, but did not reach statistical significance compared to HF. (F) The NAFLD activity score
was reduced in HFCL and a tended to be reduced in HFL and HFC. *p < 0.05 versus HF. #p < 0.05 versus HFL. Individual values with medians
(line). n = 10.
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p = 0.0243), HFL (p < 0.0001 and p = 0.0134) and HFC
(p < 0.0001 and p = 0.0389) 2 weeks after intervention, but
did not differ between groups at any other time-points (fig. 3).
ALP did not differ between the groups (table 2).
Hepatic oxidative stress.
Total levels of the water-soluble antioxidant vitamin C were
higher in HFC livers compared to HF (p = 0.0099), HFL
(p < 0.0001) and HFCL (p = 0.0014) despite identical vita-
min C content in the diets, whereas levels of the oxidized
form of vitamin C, DHA, did not differ between groups.
Liraglutide increased the fat-soluble antioxidants a-tocopherol
in HFL compared to HF (p < 0.0154), HFC (p = 0.0023) and
HFCL (p = 0.0012) and c-tocopherol compared to HFC
(p = 0.013). MDA, a marker of lipid oxidation, was increased
in HFCL compared to HF (p < 0.0001), HFL (p = 0.0021)
and HFC (p = 0.017). There were no differences in hepatic
antioxidants SOD, GSH and GSSG, %GSSG, or the oxidative
stress markers L-arginine, ADMA and the L-arginine/ADMA
ratio between groups (table 2).
Dyslipidaemia.
Plasma TC, TG and fractionated (VLDL-TG, VLDL-C, LDL-
C and HDL-C) lipoprotein levels confirmed an equal degree
of dyslipidaemia in all groups before intervention (week 0).
Measurements were obtained at two additional time-points;
weeks 2 and 4 (termination) after intervention (table 3) (for
reference TC = 1.16 [0.92–1.45] mM, LDL-C = 0.99 [0.74–
1.31] mM and TG = 1.02 [0.80–1.31] in guinea pigs fed a
chow diet for 25 weeks [17]). HFL animals displayed an
increase in VLDL-TG (p = 0.0254) compared to HFCL at
week 2, but was otherwise not significantly different from the
other groups. In the HFC group, TC was decreased after 2
and 4 weeks compared to both HF (p = 0.0005 and
p = 0.0175, respectively) and HFL (p < 0.0001 and
p = 0.0056, respectively) animals on both time-points. A simi-
lar pattern was observed in HFCL, although the reduction in
TC only reached statistical significance compared to HFL ani-
mals at week 2 (p = 0.0006). After 2 and 4 weeks, VLDL-C
(p < 0.0001 and p = 0.0034) and LDL-C (p < 0.0001 and
p = 0.0063) were decreased in HFC animals compared to HF.
In the HFCL group, VLDL-C was decreased compared to HF
at week 2 (p = 0.0183) and compared to HFL at weeks 2
(p < 0.0001) and 4 (p = 0.023), whereas LDL-C was
decreased at week 2 compared to HFL (p < 0.0001). VLDL-
TG was also found to be decreased in HFCL animals com-
pared to HFL animals at week 2 (p < 0.0254). At week 4,
free fatty acids (FFA) were significantly increased in HFL
compared to HF (p = 0.0217) and HFC (p = 0.0396) and in
HFCL compared to HF (p = 0.0412) (table 4). On all other
time-points and measures of dyslipidaemia, groups did not dif-
fer significantly.
Plasma markers of oxidative stress.
Plasma vitamin C levels were significantly lower in HFL and
HFCL compared to HF and HFC (p < 0.05), whereas DHA
and the DHA/vitamin C ratio (Table S2) were equal between
groups. Circulating levels of L-arginine, ADMA (Table S2),
the L-arginine/ADMA ratio and 8-isoprostanes were not differ-
ent between groups. The BH2/BH4 ratio was increased in
HFCL compared to HF (p = 0.0237) and HFC (p = 0.0124;
table 4).
Endothelial dysfunction.
The acetylcholine receptor agonist carbachol induced vasodila-
tion that was completely abolished by the nitric oxide synthase
Table 2.
Liver status at euthanasia (week 4 post-intervention)
HF HFL HFC HFCL
Relative liver weight (%) 5.72  1.89 4.61  1.24 3.53  0.83** 4.00  1.13*
Cholesterol (lmol/g tissue) 40.8  9.18 33.3  8.12 23.4  6.99***,# 23.1  6.83***,#
Triglycerides (lmol/g tissue) 52.5  11.3 57.4  8.85 47.2  18.6 40.1  16.5
Glycogen1 (lmol/g tissue) 55.7 (38.8–80.0) 32.9 (22.9–47.2) 28.4 (19.7–40.7) 18.5 (12.2–28.1)**
Plasma ALP (U/l) 47.0  10.1 48.6  7.56 56.4  10.4 59.5  13.4
Total vitamin C (nmol/g tissue) 500  95.5 422  102 661  94.3**,### 465  134††
DHA (nmol/g tissue) 9.44  15.9 9.00  7.85 3.14  7.65 7.42  4.67
a-Tocopherol (nmol/g tissue) 25.5  10.0 41.8  17.6* 21.9  8.31## 20.7  6.90##
c-Tocopherol (nmol/g tissue) 1.27  0.75 2.13  1.25 0.95  0.54# 1.23  0.47
GSH (nmol/g tissue) 3902  644 3999  761 3569  368 3804  674
GSSG (nmol/g tissue) 209  77.3 246  62.5 208  81.5 208  60.6
% GSSG2 5.13  1.96 6.02  2.12 5.41  1.65 5.33  1.66
MDA (nmol/g tissue) 136  29.9 174  52.6 192  54.2 265  67.0***,##,†
SOD (U/g tissue) 1669  231 1803  599 2168  419 2117  624
L-arginine/ADMA1 621 (351–1101) 909 (513–1609) 364 (206–646) 433 (245–767)
ADMA, asymmetric dimethylarginine; ALP, alkaline phosphatase; DHA, dehydroascorbic acid; GSH, glutathione; GSSG, oxidized glutathione;
MDA, malondialdehyde; SOD, superoxide dismutase.
1Geometric means with 95% confidence intervals.
2Calculated as GSSG/(GSH + GSSG). n = 10.
*p < 0.05, **p < 0.01 ***p < 0.001 versusHF. #p < 0.05, ##p < 0.01, ###p < 0.001 versusHFL. †p < 0.05 ††p < 0.01 versusHFC.Means with S.D.
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inhibitor Nx-nitro-L-arginine methyl ester hydrochloride
(L-NAME) (p < 0.001 at all concentrations of carbachol) in
both HF and HFL. The cyclooxygenase inhibitor, indometha-
cin, also reduced carbachol-induced vasodilation, although this
was only significant for the HF group at carbachol concentra-
tions of 107 M (p = 0.0035), 3 9 107 M (p < 0.0001) and
106 M (p = 0.0338; fig. 4).
Discussion
Treatment with the GLP-1 analogue liraglutide in guinea pigs
reduced NASH progression by ameliorating hepatic inflamma-
tion and hepatocyte damage (ballooning), while dietary inter-
vention decreased dyslipidaemia and tended to reduce hepatic
steatosis and ballooning. These results imply the applicability
of GLP-1 treatment in lean NASH. The differential effect on
liver histology and circulating lipids of the two applied inter-
ventions suggests a potential benefit of combined treatment in
lean NASH, albeit the limitations of the present study weakens
conclusions regarding such effects.
The need to study the effectiveness of treatment modalities
on lean NASH and its associated comorbidities is underlined
by the relatively high prevalence and unique phenotype of this
disease [5,6]. Previous studies from our laboratory have
recorded that the high-fat feeding regime also applied in the
current study does not induce excessive weight gain compared
to chow, nor promotes excessive deposition of body fat com-
pared to chow-fed controls, confirming the guinea pig as a
non-obese (lean) animal model of NAFLD and NASH
[16,17]. The present findings indicate that liraglutide exerts
similar effects on NASH histopathology in lean guinea pigs as
previously reported in clinical and pre-clinical settings utiliz-
ing obese individuals and animals [9–15,34,35]. Notably, the
beneficial effects of treatment with liraglutide occurred in the
presence of severe (grade 3) fibrosis. This is interesting as uni-
variate analysis of individuals treated with liraglutide for
48 weeks, found that patients with severe (grade 3–4) fibrosis
at baseline were less likely to respond to liraglutide [15]. In
support of this, switching spontaneous hypertensive stroke
prone rats from a high-fat diet to a low-fat diet only reversed
hepatic steatosis and down-regulated inflammatory genes and
liver enzymes if the intervention took place before the devel-
opment of fibrosis [36]. The presence of advanced NASH in
the guinea pigs therefore could render them less responsive to
treatment. Nevertheless, liraglutide decreased hepatic inflam-
mation and hepatocyte ballooning, but it is currently not clear
if these anti-inflammatory effects result from direct actions on
immune cells or are secondary to metabolic and weight loss
effects [37]. However, the absence of hepatocyte GLP-1 recep-
tors implies that histological improvements are mediated by
indirect effects of liraglutide [38,39]. Studies in obese murine
NASH models have suggested that liraglutide decreases endo-
plasmic reticulum stress and TNF-a levels in the liver, both of
which are believed to play key roles in NASH [11,13]. It
remains to be investigated if similar mechanisms underlie the
effect of liraglutide in lean NASH. The histological improve-
ment by liraglutide was associated with enhanced hepatic a-
tocopherol (vitamin E) content. The positive effects of liraglu-
tide may then be linked to vitamin E associated effects as ran-
domized clinical trials have found vitamin E to improve
NASH histology in both adults and children [40,41].
As other included markers of hepatic redox status were not
affected by liraglutide in the current study, it may be sug-
gested that the effect of liraglutide is not exclusively linked to
reduction in hepatic oxidative stress [42]. Based on both clini-
cal and pre-clinical studies [9–15,34,35], we expected liraglu-
tide to decrease hepatic steatosis, but surprisingly steatosis
grade and hepatic triglyceride content were similar between
liraglutide-treated animals and high-fat controls. FFA are
implicated in the pathogenesis of NASH and increased supply
of fatty acids, due to enhanced lipolysis in the adipose tissue,
may directly cause steatosis [4]. Liraglutide-treated animals
exhibited an increase in circulating FFA, likely resulting from
the weight loss. These FFA may then have been taken up by
the liver preventing a potential antisteatotic effect of liraglu-
tide. Prolonging the treatment duration to ensure weight stabil-
ity after the initial weight loss may then be necessary to
reduce hepatic steatosis. In mice with steatosis, liraglutide
increased mRNA levels of microsomal triglyceride transfer
protein (MTTP) and apoB, suggesting that enhanced hepatic
lipid export is involved in decreasing liver lipid levels after
liraglutide treatment [9]. In human beings and rats, advanced
disease appears to compromise hepatic lipid out-flow, as the
expression of MTTP was decreased in NASH [43–45]. The
unchanged hepatic triglyceride levels in the current study
could reflect the presence of advanced NASH at the time of
Fig. 3. Liver enzymes. (A) ALT and (B) AST were increased in HFCL compared to the other groups two weeks after initiating the intervention
(p < 0.001 and p < 0.05, respectively), but remained similar between groups at all other time-points. Geometric means with 95% confidence inter-
vals. n = 5–10. Previous reported values for chow-fed controls ALT: 37.0 (29.2–46.9) U/l, AST: 43.6 (30.7–61.8) U/l [17].
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intervention, as well as the relatively short intervention period
in which weight stability was not obtained. In murine models
where liraglutide decreased steatosis, the animals were obese
and glucose intolerant/insulin-resistant [9–14,46,47]. The effect
of liraglutide in these animals could, in part, be ascribed to a
reduction in hyperglycaemia and subsequent prevention of glu-
cose-induced de novo lipogenesis [16,17,19,48]. The absence
of glucose intolerance and obesity in the lean guinea pig
NASH model [16,17] is in accordance with the observation
that insulin resistance is not universally present in lean NASH
patients [8] and may help account for the unaffected hepatic
steatosis after liraglutide treatment. The absence of glucose
intolerance also allows the current study to dissociate a hepatic
effect of liraglutide from an effect promoted by liraglutide’s
ability to improve glucose metabolism. In addition, steatosis
rather than NASH per se may have been present in the previ-
ously described murine models as only a single study con-
firmed NASH histologically [13]. Furthermore, fibrosis was
described as mild in another mouse study [47], rendering the
reported effects targeting steatosis and possibly early stages of
NASH in these animal models. Whether intervention at an ear-
lier disease stage, and/or longer duration of treatment, will
exert more profound effects on the steatosis grade in lean
NASH, remains to be investigated.
Dyslipidaemia was improved by dietary intervention reduc-
ing circulating levels of TC, VLDL-C and LDL-C in HFC and
HFCL groups compared to HF. However, lipid concentrations
were still higher compared to previously reported levels from
healthy control guinea pigs fed a chow diet for 25 weeks [17].
The effect was most pronounced in HFC, likely due to the
rapid weight loss of HFCL expected to affect lipid metabolism
and increase hepatic MDA [49]. Hepatic histopathology was
considerably improved after dietary intervention but did not
reach statistical significance. Reports from rats have shown
that switching to a normal low-fat diet for 8 weeks after
8 weeks of high-fat diet ameliorated dyslipidaemia as well as
hepatic steatosis and inflammation [50]. Thus, prolonged treat-
ment duration may be necessary to reverse NASH via dietary
intervention, especially considering the advanced disease stage
in the current model, exhibiting hepatic fibrosis, which was
not apparent in the rat model [50]. Furthermore, two animals
of the HF group presented a very low steatosis grade. This
was highly unexpected in comparison with our previous gui-
nea pig studies [16,17], where a high degree of steatosis was
consistently found in high-fat-fed groups. However, as HFC
and HFCL animals displayed a significantly lower steatosis
grade compared to HFL animals, the lack of significance when
comparing to the HF group is most likely due to these isolated
animals representing biological variation or a yet undetermined
underlying cause. Indeed, HFC (p < 0.05) and HFCL
(p < 0.05) had a lower degree of steatosis compared to HF
when excluding these two animals from the statistical analysis.
However, no experimental justification could support this
exclusion; hence, the statistical analysis was based on the full
sample size. Oxidative stress is a key finding in both patients
and animals with NAFLD [3]. After dietary intervention, hep-
atic oxidative stress was reduced, evident by increased vitamin
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C levels. We have previously reported that high-fat diets
decrease hepatic vitamin C content in guinea pigs [16,51] sug-
gesting that inadequate vitamin C status may contribute to the
development of NASH [52]. As absolute food intake was not
increased in HFC compared to HF (data not shown), improve-
ments in hepatic vitamin C status are likely to reflect an aug-
mentation of the antioxidant system and not just increased
dietary intake. Liver vitamin C levels were not different in
HFC and HFL/HFCL when adjusting for food intake, suggest-
ing that lower vitamin C levels in these groups were caused
by lower food intake. Conversely, plasma vitamin C adjusted
for food intake did not differ between groups (data not
shown), again implying decreased food intake as the cause for
lower vitamin C and not liraglutide per se.
In a large Asian cohort study, non-obese individuals with
NAFLD were found to be at significantly increased risk of
cardiovascular disease especially if the NAFLD had pro-
gressed to NASH [53]. Consequently, we investigated the
endothelial function in coronary arteries from the HF and
HFL group, but did not find an effect on liraglutide on
vasodilation. This is in agreement with circulating markers of
oxidative stress and endothelial function, as levels of 8-iso-
prostanes and BH2/BH4 and L-arginine/ADMA ratios were
not different between groups. We have previously reported
the absence of atherosclerotic lesions in the aorta of guinea
pigs fed a high-fat diet for 16 weeks. It is therefore possible
that the current experimental set-up does not induce vascular
dysfunction [16]. Alternatively, the speculated effect of
liraglutide may not be associated with carbachol-mediated
vasodilation in guinea pigs within the duration of the inter-
vention period.
Limitations of the present study include the adjustments
made in liraglutide dose in the HFCL group, necessary to
comply with the humane end-point of 20% weight loss. The
decision not to include a chow-fed control could be argued
to be a limitation of the experimental design. However, we
have previously and repeatedly reported that high-fat diets
comparable to the one applied in the current study, in a set-
up closely resembling the current study, do not enhance
weight gain or body fat deposition in guinea pigs when
compared to a chow-fed control, confirming the lean pheno-
type of model [16,17]. It should be noted that high-fat-fed
guinea pigs do not exhibit any form of growth retardation,
nor display any clinical signs of malnutrition or
disease. In addition, the 4-week duration of the intervention
period may have been too short to detect changes in steato-
sis and fibrosis in the current model. We have previously
demonstrated that long-term (25 weeks) high-fat feeding in
guinea pigs induces NASH with concomitant fibrosis [17].
As similar hepatic changes were confirmed in the HF group
of the current study, this clearly suggests that the observed
histological improvement in HFL animals was due to
liraglutide. However, as pre-intervention biopsies were not
obtained, it cannot be ruled out that liraglutide delays the
development of, rather than reversing NASH.
In conclusion, this pre-clinical study in non-obese guinea
pigs with advanced NASH found dietary intervention to
improve dyslipidaemia and reduce liver cholesterol and
weight, although potential effects related to NASH histology
may require a longer intervention period. Liraglutide improved
key histological features of NASH and hepatic markers of
oxidative stress, even in the setting of severe fibrosis and a
persistent intake of high-fat and cholesterol. These results sug-
gest GLP-1 analogues as a potential treatment option in non-
Table 4.
Plasma lipids and markers of oxidative stress at euthanasia (week 4 post-intervention)
HF HFL HFC HFCL
Total vitamin C (lM) 44.3  15.6 26.2  10.8* 41.5  9.23# 23.1  12.6**,†
DHA (lM) 0.30  1.52 0.28  0.59 0.49  0.44 0.08  0.38
FFA (mM) 0.36  0.09 0.53  0.13* 0.37  0.08# 0.52  0.18*
8-Isoprostanes (ng/l) 55.2  17.2 57.7  22.3 54.3  10.3 51.1  15.8
L-arginine/ADMA1 169 (142–197) 204 (150–258) 166 (139–193) 207 (160–254)
BH2/BH4 0.15  0.04 0.20  0.06 0.14  0.02 0.21  0.06*,†
DHA, dehydroascorbic acid; FFA, free fatty acids.
1Geometric means with 95% confidence intervals. n = 10. ADMA: asymmetric dimethylarginine. BH2: dihydrobiopterin. BH4: tetrahydrobiopterin.
*p < 0.05, **p < 0.01 versus HF. #p < 0.05 versus HFL. †p < 0.05 versus HFC. Means with S.D.
Fig. 4. Endothelial function by myography. Carbachol induced vasodi-
lation in HF- and HFL-treated animals, which could be inhibited by
L-NAME. Indomethacin tended to reduce carbachol-induced vasodila-
tion, but this was only significant for HF at carbachol concentrations
of 107, 3 9 107 and 106 M. ***p < 0.001 HF(L-NAME) and
HFL(L-NAME) versus HF/HFL or HF/HFL(Indomethacin). #p < 0.05
##p < 0.01 ###p < 0.001 HF(Indomethacin) versus HF. Means with
S.D. n = 8 (HF, HF L-NAME,) n = 7 (HFL, HF Indomethacin and
HFL Indomethacin) n = 6 (HFL L-NAME) (variable group sizes due
to exclusion of segments with a contraction <1 mN/mm). L-NAME:
Nx-nitro-L-arginine methyl ester hydrochloride.
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obese NASH should the observed effects translate to human
beings.
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